Probiome Therapeutics is a newly formed Iowa-based company in Ames. It stems from a multi-disciplinary team of very talented scientists who are dedicated to promoting collaborative translational research, technology transfer, entrepreneurship and commercialization in an emerging area of gut microbial genetic engineering and pharmacogenomics to address incurable chronic conditions including neurological and infectious diseases. In the past couple of years, the team has been reengineering probiotic EcN drug delivery through the gut-CNS axis to combat. Probiome intends to develop innovative oral probiotic-based therapy to improve the health of patients with major diseases including neurodegenerative diseases and COVID19.
As a development-stage company Probiome Therapeutics Inc values its success on partnership, collaboration and equity investment from pharmaceutical industries and venture capital investment.
We are continually looking for business partners/collaborators/ investors who can see the true long-term value of investment in this company.